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Abstract
Aims/hypothesis Type 1 diabetes is the most frequent endo-
crine disease in children, with 65,000 children diagnosed
worldwide every year. Up to 80% of these children present
with diabetic ketoacidosis (DKA), which is associated with
both short-term risks and long-term consequences. This
study aimed to characterise the worldwide variation in pre-
sentation of type 1 diabetes to inform future interventions to
reduce this excess morbidity and mortality.
Methods This was a systematic review of studies indexed on
PubMed, EMBASE, Web of Science, Scopus or CINAHL
before March 2011 that included unselected groups of chil-
dren presenting with new-onset type 1 diabetes, reported the
proportion presenting with DKA and used a definition of
DKA based on measurement of pH or bicarbonate.
Results Sixty-five studies of cohorts comprising over 29,000
children in 31 countries were included. The frequency of
DKA at diagnosis ranged from 12.8% to 80%, with highest
frequencies in the United Arab Emirates, Saudi Arabia and
Romania, and the lowest in Sweden, the Slovak Republic and
Canada. Multivariable modelling showed the frequency of
DKA was inversely associated with gross domestic product,
latitude and background incidence of type 1 diabetes.
Conclusions/interpretation This is the first description of the
variation in frequency of DKA at presentation of type 1
diabetes in children across countries. It demonstrates large
variations that may, at least in part, be explained by different
levels of disease awareness and healthcare provision and
suggests ways to decrease the excess morbidity and mortality
associated with DKA at diagnosis.
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Introduction
Diabetic ketoacidosis (DKA) is a metabolic derangement
characterised by the triad of hyperglycaemia, acidosis and
ketosis that occurs in the presence of very low levels of
effective insulin action. It is the leading cause of mortality in
children with type 1 diabetes [1, 2] and is associated with
increased morbidity and healthcare expenditure: DKA at
diagnosis is associated with a lower frequency of partial
remission [3, 4] and less residual beta cell function [5, 6],
and the mean excess medical expenditure for one episode of
DKA is over US$3,500 [7]. The psychological effect of
DKA at onset of type 1 diabetes has not been studied, but
children later hospitalised with DKA have a higher number
of psychiatric disorders, lower self-esteem and social com-
petence and worse relationships with their parents [8].
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Worldwide, approximately 65,000 children aged under
15 years develop type 1 diabetes each year [9] and up to
80% present with DKA. The worldwide variation in the
incidence of type 1 diabetes in children has been well charac-
terised by the WHO’s Diabetes Mondiale (DiaMond) project
[9, 10], using standardised incidence data from 57 countries
from 1990 onwards. Annual age-adjusted incidence varies
over 350-fold, ranging from 0.1/100,000 in China to 40.9/
100,000 in Finland [9]. However, there is less evidence
concerning the frequency of DKA at diagnosis. Data from
24 centres in Europe collected as part of the EURODIAB [11]
project reported DKA frequency at diagnosis that varied from
11% to 67%, and an inverse correlation between background
incidence of type 1 diabetes and frequency of DKA in 11 of
the 24 centres. The variation in frequency of DKA at diagno-
sis of type 1 diabetes in children worldwide, however, remains
largely uncharacterised.
Characterising this variation is an important step towards
identifying possible explanations for the differences and
potentially informing the design of interventions to decrease
rates of DKA. We have previously shown that, at an indi-
vidual level, younger age, diagnostic error, ethnic minority
status, lack of health insurance, lower body mass index,
preceding infection, and delayed treatment are all associated
with an increased risk of DKA, while having a first-degree
relative with type 1 diabetes at the time of diagnosis and
higher parental education appear to be protective [12]. We
therefore aimed to systematically review the effects of coun-
try characteristics on the frequency of DKA to provide the
first comprehensive synthesis of worldwide data on the
frequency of DKA and explore possible reasons for the
variation.
Methods
Search strategy The search strategy has been previously
described [12]. We searched five electronic bibliographic
databases (PubMed, EMBASE, Web of Science, Scopus
and CINAHL) from inception to March 2011 using a com-
bination of subject headings and free text incorporating
‘diabetic ketoacidosis’, ‘diabetes and ketoacidosis’ and ‘di-
agnosis’ and limited to infants, children or adolescents (see
electronic supplementary material [ESM] Methods for com-
plete search strategy). We also manually screened the refer-
ence lists of all included papers.
Study selection Included studies fulfilled all of the follow-
ing criteria: (1) published as a primary research paper in a
peer-reviewed journal; (2) included cohorts of children and
young people presenting with new-onset type 1 diabetes
who had not been selected based on other characteristics;
(3) reported the proportion of children presenting with
DKA; and (4) included a measurement of either pH or
bicarbonate in the definition of DKA. We chose to include
studies that defined DKA based on measurement of either
pH or bicarbonate as we wanted the search strategy to be
broad enough to include studies from different international
settings but rigorous enough to ensure that we were consis-
tently identifying those children with objective evidence of
metabolic derangement. We excluded studies of only highly
selected groups, for example neonates, children being trea-
ted with high-dose steroids or receiving chemotherapy, as
well as drug trials and conference proceedings. No restric-
tions were made for language, sample size or period of
study, and we included all studies that included children
and young people up to age 21.
One reviewer (JUS) performed the search and screened
the titles and abstracts to exclude papers that were clearly
not relevant. Full-text articles were reviewed by at least two
reviewers (JUS and FMW/MT) to assess eligibility, and
consensus was used to resolve any disagreement between
researchers. When either the definition of DKA was not
given or we were unable to adequately interpret the data
presented, we contacted authors for clarification. We also
contacted the authors if papers reported collective data from
multiple centres in order to obtain disaggregated data.
Quality assessment We applied the Critical Appraisal Skills
Programme guidelines for case–control and cohort studies
as a framework for quality assessment and excluded studies
with major limitations in methods or reporting [13]. Data
concerning study size, period of study, design (prospective
or retrospective) and method of case identification were
extracted and used as markers of quality for analysis.
Data extraction and synthesis Characteristics of included
studies were extracted independently by at least two
researchers (JUS and FMW/MT) using a standardised form.
These included markers of quality as well as the country or
region of the study, eligible age range and definition of
DKA. For studies that recruited children over more than
one time period, we used data only from the most recent
period, where possible. If this was not possible, data from all
time periods were combined.
Analysis Multivariable regression analysis was performed
using R (version 2.15.1) with frequency of DKA as the
dependent variable and four features of the country where
the study was performed (background incidence of type 1
diabetes, gross domestic product [GDP], expenditure on
healthcare as a percentage of GDP, and latitude) as indepen-
dent variables. In addition, we included four study-level
characteristics (study size, period of study, design and meth-
od of case identification) in the regression analysis. The
inclusion of study size provided a weighting for each study
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and adjustment for potential confounding by the number of
children included in each study. The period of study, design
and method of case identification in turn allowed adjustment
for changes in the background incidence and diagnosis of
type 1 diabetes over time, the possibility of recording and
recall bias in retrospective studies and the rigour of case
identification. At the country level, the background inci-
dence of type 1 diabetes was included as it has been shown
to be related to the frequency of DKA. GDP and expenditure
on healthcare as a percentage of GDP were included to
explore the effects of economic and healthcare factors on
the frequency of DKA, and latitude because the incidence of
type 1 diabetes has been reported to vary with latitude [14,
15]. Other potential confounding factors identified previous-
ly, such as age, ethnicity and family history of type 1
diabetes could not be included as few studies reported on
these individual characteristics of recruited children.
We defined study size as the total number of children
with type 1 diabetes included in the study. The study period
was converted to a numerical scale using the mid-year of
each study and numbering each year upwards from zero for
the earliest study. Study design and method of case identi-
fication were dichotomised as follows: design as prospective
or retrospective; and method of case identification as inter-
nal hospital or clinic records (children recruited by examin-
ing hospital or clinic records or by requesting local
healthcare workers to examine records to provide a list) or
external register, database or surveillance cohort (children
identified via externally held registers or databases or
through established surveillance cohorts). In the last group,
the external registers and databases included registers for
drug reimbursement, registration for exemption from pay-
ment for medication, national drug registries and systems
for insulin delivery. This distinction was selected as we felt
studies that relied solely on internal hospital or clinic
records were at greater risk of inclusion bias.
The background incidence of type 1 diabetes was
obtained from the included studies or those performed by
the same research group that reported rates for the same
population. When this was not possible, a literature search
was performed by first reviewing the reference list of the
study and then searching PubMed for studies reporting
DKA incidence in the city, region or country. Where possi-
ble, incidence data from the same city or region were used,
but where such data were not available, data for the whole
country or the closest region in the country for which data
were available were used. Data were not available for two
countries (Turkey and the United Arab Emirates), so values
from neighbouring countries (Jordan and Oman) were used,
as in the International Diabetes Federation Diabetes Atlas
[16]. To allow for changes in the background incidence of
type 1 diabetes over time, values were only used when the
period of collection of the incidence data included the mid-
year of the study period. If values were available for indi-
vidual years, the incidence in the mid-year of the study
period was used.
The latitude of the location of each study was obtained
from the online World Atlas (www.worldatlas.com,
accessed 23 June 2012) and the modulus of the latitude used
for analysis. When studies were nationwide or included
multiple centres within a country, the latitude of the mid-
point of the country was used.
We obtained the GDP for each country for the mid-year
of each study from the International Monetary Fund World
Economic Outlook Database (www.imf.org/external/pubs/
ft/weo/2011/01/weodata/index.aspx, accessed 30 Oct
2011). For two countries (the Slovak Republic and Slov-
enia) values were not available for the mid-year of the study
(1991) so values from 1993 and 1992, respectively, were
used which were still within the period of study.
The expenditure on healthcare as a percentage of GDP
was obtained for the mid-year of each study using the WHO
Global Health Observatory Data Repository (www.who.int/
gho, accessed 23 June 2012) for studies after 1995, and the
Organisation for Economic Co-operation and Development
Health Data (http://stats.oecd.org, accessed 23 June 2012)
for those before 1995 (when WHO data were not available).
Data were not available for the mid-year of the study for ten
studies, so values from 1995 were used, which were still
within 2 years of the study period. Data were not available
for any years within 2 years of the period of study for one
study (Table 2).
Generalised linear modelling for proportion data and
standard linear modelling showed significant overdispersion
and heteroscedasticity, respectively. Box–Cox analysis sug-
gested a log transformation and this was found to model the
data well. We therefore used multivariable linear regression
of log transformed DKA frequencies against the explanatory
variables. Stepwise removal of non-statistically significant
variables with ANOVA testing at each step showed that
removal of any of the variables did not affect the others.
Results
After duplicates were removed, the search identified 1,441
papers, of which 1,333 were excluded as clearly irrelevant
and a further 63 after full-text assessment. There was com-
plete agreement between researchers throughout this pro-
cess. The most common reasons for exclusion were failure
to use a definition of DKA that included either pH or
bicarbonate, duplication of data or no data for children with
new-onset diabetes (Fig. 1). Two studies were excluded
based on quality alone. The first because we were unable
to adequately interpret the numerical data after contacting
the author, and the second because of a large amount of
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missing data. A further 12 papers were identified through
citation searching. One paper compared incidence of type 1
diabetes at presentation between south-east Sweden and
Lithuania and so is reported as two studies [17]. Another
[11] reported the mean frequency of DKA across 24 centres
in Europe. After contacting the authors we were able to
obtain data for 11 of these centres individually. Results from
three of these centres had been reported in other included
papers in greater detail, leaving eight studies for inclusion
from that paper. This review is therefore based on 65
studies.
The 65 included studies provided data on over 29,000
children (range 10 to 3,947) from 31 countries across five
continents (two from Asia, 21 from Europe, three from the
Middle East, two from North America, two from Oceania,
and one from South America) (Table 1). Notably, many
large countries, such as South American countries, India,
China and Japan, are not represented and there are no
studies for the whole continent of Africa. All included
studies were cohort studies. Most recruited children retro-
spectively from hospital or clinic records, with study lengths
ranging from 1 to 17 years, and the periods of study covering a
30 year period from 1978 to 2008. Most included children up
to age 15 (n029), 16 (n05) or 18 years (n013), with eight
studies including young people between 18 and 21 years and
one only those under 6 years. There was a wide range of
definitions of DKA, all of which included either pH ≤7.2 to
<7.36 or bicarbonate <15 to ≤21 mmol/l.
Frequency of DKA across countries Table 2 shows the
frequency of DKA at diagnosis in each study, together with
the background incidence of type 1 diabetes, latitude, GDP
and expenditure on healthcare as a percentage of the coun-
try’s GDP. The frequency of DKA varied sixfold, from
12.8% in Sweden to 80% in the United Arab Emirates and
from 16% to 67% when only those studies defining DKA by
pH<7.3 were included. Ranking of countries according to
frequency of DKA (Fig. 2) demonstrated that the highest
frequencies were seen in the United Arab Emirates (80%),
Romania (67%), Taiwan (65%) and Saudi Arabia (59%) and
the lowest in Sweden (14%), Canada (18.6%), Finland
(22%) and Hungary (23%).
Multivariable linear regression Three studies had incom-
plete data (Table 2) and were, therefore, excluded from the
regression modelling. Initial linear modelling showed that
GDP and latitude were strongly collinear and therefore it
was only possible to include one. Latitude was chosen as it
explained more of the variation.
The final model (Table 3) shows that latitude and back-
ground incidence of type 1 diabetes were significantly
associated with frequency of DKA, with frequency decreas-
ing progressively with distance from the equator and in
areas with a higher background incidence of type 1 diabe-
tes. Although not reaching statistical significance, there was
also an inverse association between expenditure on health-
care as a percentage of GDP and frequency of DKA. No
significant associations were found for study size, period of
study, design or method of case identification. These asso-
ciations were the same when latitude was replaced with
GDP, showing that GDP is also inversely associated with
frequency of DKA.
Additional records identified
through reference lists
(n=12)
Records screened after duplicates removed
(n=1,441)
Records excluded
(n=1,333) 
Full-text articles assessed
for eligibility
(n=108)
Inadequate definition for DKA given n=11
Not new onset diabetes n=8
Type 2 diabetes / mixed type 1 and 2 n=7
No separate data on children n=6
No reference to DKA n=6
No comparison between DKA and non-DKA n=5
Duplicate data n=9
Unable to obtain n=3
Case series n=1
Unable to confirm unselective sampling n=5
Unable to clarify missing data n=2
Full-text articles excluded
(n=63)
Articles included in
synthesis
(n=57)
PubMed
(n=602)
Scopus
(n=957)
CINAHL
(n=40)
EMBASE
(n=390)
Web of Science
(n=243)
Studies included in
synthesis
(n=65)
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Fig. 1 PRISMA (www.prisma-
statement.org) flow diagram
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After adjusting for study size, period of study, design,
method of case identification, expenditure on healthcare as a
percentage of GDP, and latitude, the frequency of DKA
decreased by approximately 10% as the annual background
incidence increased from 10 to 30 cases per 100,000, with
greater changes at lower background rates. R2 for the model
was 0.56, indicating that a large amount of the variation was
explained by these factors.
Discussion
Principal findings This systematic review provides the first
comprehensive synthesis of the international variation in
frequency of DKA at presentation of type 1 diabetes in
children. The frequency of DKA at diagnosis ranges from
12.8% to 80%, and is lowest in Sweden, the Slovak Repub-
lic and Canada and highest in the United Arab Emirates,
Saudi Arabia and Romania. The frequency of DKA is lower
in countries where the background incidence of type 1
diabetes is higher and in countries further from the equator
and with a lower GDP. Although not statistically significant,
there is also an association (p00.058) between frequency of
DKA and expenditure on healthcare as a percentage of GDP.
The association with background incidence may be due to
increased awareness of the condition and hence earlier de-
tection, or it may reflect a different subtype of disease. The
association with latitude may similarly reflect different sub-
types of disease or geographical factors and is also likely to
include socioeconomic factors, including GDP and health
expenditure. The importance of these findings is that they
suggest the variation may, at least in part, be explained by
different levels of awareness of the disease and healthcare
provision. Given that these factors are amenable to change,
there is the potential to decrease the excess morbidity, mor-
tality and healthcare expenditure associated with DKA at
diagnosis.
Strengths and limitations Our broad inclusion criteria and
systematic search encompassing multiple databases, not
limited by language or study size, provided data on over
29,000 children from 31 countries. While this allows us to
make comparisons across multiple countries, it also
increases the heterogeneity of the included studies. In most
studies, the primary source of ascertainment was internal
hospital records or notifications by paediatricians and family
doctors, with only 19 studies including a secondary source.
Furthermore, many of the studies were retrospective and
relied on hospital records for the data and so are subject to
recording and recall bias. However, these factors (method of
case identification and study design) and study size and
period were not associated with the variation in frequency
of DKA, suggesting that they are unlikely to account for the
differences seen. This cannot, however, adjust for variations
in ascertainment of both children with type 1 diabetes and
those with DKA. It also fails to take account of other
potential confounding factors such as age, ethnicity and
family history of type 1 diabetes, which have been described
previously [12]. Unfortunately, few studies reported individ-
ual characteristics of recruited children so these could not be
included in the modelling.
Included studies also used a wide range of definitions of
DKA, reflecting different international settings and periods of
study. Only one [18] used the current diagnostic criteria for
DKA published by the International Society for Paediatric and
Adolescent Diabetes [19]. However, our inclusion criteria
limited studies to those with a measurement of pH (pH≤7.2
to <7.36) and/or bicarbonate (<15 to≤21 mmol/l) and so,
while being broad enough to include studies from different
countries, consistently identified those with worse metabolic
derangements. Although the absolute frequency of DKA may
vary with different definitions, it is unlikely that this alone
would account for the variations seen. The wide range of
definitions used precluded comprehensive sensitivity analy-
ses, but inclusion of only those studies defining DKA by a pH
<7.3 (n018) still demonstrated a variation from 16% (in
Sweden) to 67% (in Romania) (Fig. 2).
Although the included studies represented 31 countries,
21 of these—providing data for 18,164 (62%) of the chil-
dren—were European. The USA and Canada accounted for
a further 7,873 (27%), with only 3,122 (11%) children from
outside these countries. Many large countries, including
South American countries, India, China and Japan, were
also not represented and no studies came from any country
in Africa, where DKA is known to be a major problem [20].
This lack of data is itself an important finding of this review,
but limits the range of included values of latitude, GDP and
expenditure on healthcare as a percentage of GDP, and the
extent to which the conclusions can be generalised
worldwide.
Possible causal explanations for variation and comparison
with existing literature Although the nature of this study
prevents statements of causality and the quality of the data
limits the conclusions that can be drawn, there are a number
of explanations for why these observations might be causal.
The inverse relationship between frequency of DKA and
background incidence of type 1 diabetes worldwide is con-
sistent with previous reports of this relationship in Europe
[11]. This may reflect the overall awareness of the condition
in a given country along with the capability of its healthcare
system to quickly initiate the appropriate treatment follow-
ing diagnosis [21]. Better disease recognition through im-
proved awareness of diabetes is also supported by the
findings that children from families with higher parental
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China [89]
Oman [82]
Lithuania [11]a
Lithuania [21]
Austria [79]a
Chile [54]
Italy [69]
Italy [80]a
Italy [70]
New Zealand [55]
New Zealand [47]a
Bulgaria [78]
Germany [76]
Germany [56]
Germany [63]
Germany [11]a
USA [73]
USA [59]a
USA [3]
USA [49]a
USA and Hawaii [74]
USA [60]
USA [64]
USA [87]
USA [61]
Russia [71]
Turkey [45]
The Netherlands [11]a
Slovenia [11]a
Iceland [11]a
UK [84]
UK [81]
UK [42]
UK [68]
Slovak Republic [11]a
Slovak Republic [43]
Ireland [75]
Hungary [83]
Finland [57]
Finland [52]
Finland [88]a
Finland [53]a
Canada [46]
Sweden [51]a
Sweden [21]
Sweden [32]a
Fig. 2 Plot of the frequency
(±95% CI) of DKA at diagnosis
of type 1 diabetes per study,
grouped in countries in
descending order of the average
frequency of DKA per country.
aStudies defining DKA as
pH<7.3
Table 3 Results of multivariate
linear regression model
(loge[frequency]04.5−
0.000080×study size–0.0023×
period of study+0.10×design+
0.050×method of case identifi-
cation−0.022×expenditure on
healthcare as a percentage of
GDP−0.013×latitude−0.014×
background incidence of type 1
diabetes)
T1DM, type 1 diabetes
Variable Coefficient 95% CI p value
(Intercept) 4.5 4.4, 4.5
Study size −0.000080 −0.0011, 0.00094 0.13
Period of study −0.0023 −0.016, 0.012 0.75
Design 0.10 −0.073, 0.27 0.26
Method of case identification 0.050 −0.12, 0.22 0.58
Expenditure on healthcare as a percentage of GDP −0.022 −0.045, 0.00030 0.058
Latitude −0.013 −0.020, (−0.0050) 0.0020
Background incidence of T1DM −0.014 −0.022, (−0.0052) 0.0028
2890 Diabetologia (2012) 55:2878–2894
education are less likely to present in DKA and having a first-
degree relative with diabetes is associated with an up to six-
fold decreased risk of DKA at diagnosis [12]. However, it
remains unclear why some children present in DKA while
others do not and whether the development of DKA is a
consequence of patient or clinician delays, or whether it
indicates a particularly aggressive form of diabetes [22]. It is
possible that the observed associations reflect heterogeneity in
the underlying disease, with more aggressive disease in those
countries with lower incidence. This phenomenon may also
explain the considerable geographic variation in the preva-
lence of long-term diabetic complications [21].
There are also a number of possible explanations for
the association of frequency of DKA and latitude. The
most likely is that latitude represents a group of character-
istics for each country, including economy, healthcare
provision, access to healthcare and disease burden. The
co-linearity between latitude and GDP suggests that a
large proportion of the variation in DKA is due to differ-
ences in a country’s economic position and healthcare
provision, with a higher frequency of DKA in countries
with lower GDP and hence lower expenditure on health-
care. This is not surprising as there is robust evidence for
a similar relationship between life expectancy and GDP
[23], and poorer countries account for the largest share of
the global burden of disease [24]. Several ecological
studies have also shown that the type 1 diabetes incidence
rates correlate strongly with indicators of national pros-
perity such as GDP and low infant mortality [25, 26] and
that microalbuminuria and neuropathy are significantly
associated with health system performance, gross national
investment per capita and purchasing power [27]. How-
ever, some of the effect could reflect true geographical
differences. The increased frequencies of DKA in
countries nearer the equator may be because hotter cli-
mates lead to more rapid dehydration and metabolic de-
compensation, particularly in young children, who have
less metabolic reserve [28]. Finally, there is also growing
evidence for a role for vitamin D in the pathogenesis of
type 1 diabetes. The active metabolite of vitamin D, 1,25-
dihydroxyvitamin D, is a potent immunomodulator that
enhances the production and secretion of insulin from
beta cells, and vitamin D deficiency in utero and early
childhood is associated with an increased risk of type 1
diabetes [29–32]. Although children living near the equa-
tor are less likely to be vitamin D deficient, differences in
levels of vitamin D may contribute to the variation seen.
Unanswered questions and implications for future
research We found little or no data on the frequency of
DKA, or even type 1 diabetes, for large areas of the world,
particularly Africa and South and East Asia. Infectious dis-
eases currently dominate childhood morbidity and mortality
in these regions, so reliable indicators of diabetes and DKA
may only be possible with strengthened epidemiological
surveillance of the growing burden of non-communicable
diseases [9].
The factors addressed in this review also only account for
a proportion of the international variation, suggesting the
need for further research using standardised data including
factors known to affect the frequency of DKA and other
potential contributors, e.g. access to healthcare, population
density, genetics, patient education and healthcare resources
for diabetes. We also need to understand better the causes
and long-term consequences of DKA: in particular, whether
DKA simply reflects delayed recognition and treatment and
whether long-term clinical findings merely indicate greater
beta cell destruction at that moment, or reflect a more
aggressive form of diabetes.
Nevertheless, the finding that in some countries the fre-
quency of DKA is less than 15% and that the variation may,
at least in part, be explained by different levels of awareness
of the disease and healthcare provision, suggests there is
considerable scope to decrease the excess morbidity, mor-
tality and healthcare expenditure associated with DKA at
diagnosis of type 1 diabetes. The effect that campaigns to
improve awareness can have locally has been demonstrated
from a community intervention in Italy, in which posters
were displayed in schools, and paediatricians were provided
with blood glucometers and cards listing guidelines for early
diabetes diagnosis to give to parents; the frequency of DKA
at diagnosis fell from 78% to 12.5% [33, 34]. This review
provides support for the development and evaluation of
further country-specific diabetes education programmes,
particularly in those countries where the frequency at diag-
nosis is highest.
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